These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38989947)

  • 1. Brain-penetrating neurotrophic factor mimetics: HER-096 as a disease-modifying therapy for Parkinson's disease.
    Kulesskaya N; Holmström KM; Huttunen HJ
    Neural Regen Res; 2025 Apr; 20(4):1094-1095. PubMed ID: 38989947
    [No Abstract]   [Full Text] [Related]  

  • 2. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease.
    Lindsay RM; Altar CA; Cedarbaum JM; Hyman C; Wiegand SJ
    Exp Neurol; 1993 Nov; 124(1):103-18. PubMed ID: 8282068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER-096 is a CDNF-derived brain-penetrating peptidomimetic that protects dopaminergic neurons in a mouse synucleinopathy model of Parkinson's disease.
    Kulesskaya N; Bhattacharjee A; Holmström KM; Vuorio P; Henriques A; Callizot N; Huttunen HJ
    Cell Chem Biol; 2024 Mar; 31(3):593-606.e9. PubMed ID: 38039968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth differentiation factor 5: a neurotrophic factor with neuroprotective potential in Parkinson's disease.
    Goulding SR; Anantha J; Collins LM; Sullivan AM; O'Keeffe GW
    Neural Regen Res; 2022 Jan; 17(1):38-44. PubMed ID: 34100424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential of bone morphogenetic protein 2 as a neurotrophic factor for Parkinson's disease.
    Goulding SR; Sullivan AM; O'Keeffe GW; Collins LM
    Neural Regen Res; 2020 Aug; 15(8):1432-1436. PubMed ID: 31997802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Electroacupuncture-regulated neurotrophic factor mRNA expression in the substantia nigra of Parkinson's disease rats.
    Wang S; Fang J; Ma J; Wang Y; Liang S; Zhou D; Sun G
    Neural Regen Res; 2013 Feb; 8(6):540-9. PubMed ID: 25206697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurotrophic factors: from neurodevelopmental regulators to novel therapies for Parkinson's disease.
    Hegarty SV; O'Keeffe GW; Sullivan AM
    Neural Regen Res; 2014 Oct; 9(19):1708-11. PubMed ID: 25422631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blunt dopamine transmission due to decreased GDNF in the PFC evokes cognitive impairment in Parkinson's disease.
    Tang CX; Chen J; Shao KQ; Liu YH; Zhou XY; Ma CC; Liu MT; Shi MY; Kambey PA; Wang W; Ayanlaja AA; Liu YF; Xu W; Chen G; Wu J; Li X; Gao DS
    Neural Regen Res; 2023 May; 18(5):1107-1117. PubMed ID: 36255000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular mechanisms underlying the neuroprotection of environmental enrichment in Parkinson's disease.
    Alarcón TA; Presti-Silva SM; Simões APT; Ribeiro FM; Pires RGW
    Neural Regen Res; 2023 Jul; 18(7):1450-1456. PubMed ID: 36571341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unraveling the role of glial cell line-derived neurotrophic factor in the treatment of Parkinson's disease.
    Kakoty V; Sarathlal KC; Kaur P; Wadhwa P; Vishwas S; Khan FR; Alhazmi AYM; Almasoudi HH; Gupta G; Chellappan DK; Paudel KR; Kumar D; Dua K; Singh SK
    Neurol Sci; 2024 Apr; 45(4):1409-1418. PubMed ID: 38082050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Parkinson's Disease Comprehensive Response (PDCORE): a composite approach integrating three standard outcome measures.
    Luz M; Whone A; Bassani N; Wyse RK; Stebbins GT; Mohr E
    Brain Commun; 2020; 2(2):fcaa046. PubMed ID: 33392501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of Endurance Training on Brain-Derived Neurotrophic Factor and Inflammatory Markers in Healthy People and Parkinson's Disease. A Narrative Review.
    Małczyńska-Sims P; Chalimoniuk M; Sułek A
    Front Physiol; 2020; 11():578981. PubMed ID: 33329027
    [No Abstract]   [Full Text] [Related]  

  • 13. GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease.
    Decressac M; Ulusoy A; Mattsson B; Georgievska B; Romero-Ramos M; Kirik D; Björklund A
    Brain; 2011 Aug; 134(Pt 8):2302-11. PubMed ID: 21712347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug development in Parkinson's disease: from emerging molecules to innovative drug delivery systems.
    Garbayo E; Ansorena E; Blanco-Prieto MJ
    Maturitas; 2013 Nov; 76(3):272-8. PubMed ID: 23827471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective mechanisms by glial cell line-derived neurotrophic factor and cerebral dopamine neurotrophic factor against the α-synuclein accumulation in Parkinson's disease.
    Er S; Airavaara M
    Biochem Soc Trans; 2023 Feb; 51(1):245-257. PubMed ID: 36794783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects and Mechanisms of Exercise on Brain-Derived Neurotrophic Factor (BDNF) Levels and Clinical Outcomes in People with Parkinson's Disease: A Systematic Review and Meta-Analysis.
    Kaagman DGM; van Wegen EEH; Cignetti N; Rothermel E; Vanbellingen T; Hirsch MA
    Brain Sci; 2024 Feb; 14(3):. PubMed ID: 38539583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ''70th Birthday Professor Riederer'' induction of glial cell line-derived and brain-derived neurotrophic factors by rasagiline and (-)deprenyl: a way to a disease-modifying therapy?
    Maruyama W; Naoi M
    J Neural Transm (Vienna); 2013 Jan; 120(1):83-9. PubMed ID: 22892822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physical activity and neurotrophic factors as potential drivers of neuroplasticity in Parkinson's Disease: A systematic review and meta-analysis.
    Rotondo R; Proietti S; Perluigi M; Padua E; Stocchi F; Fini M; Stocchi V; Volpe D; De Pandis MF
    Ageing Res Rev; 2023 Dec; 92():102089. PubMed ID: 37844764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Neurotrophic Factors in Parkinson's Disease.
    Tome D; Fonseca CP; Campos FL; Baltazar G
    Curr Pharm Des; 2017; 23(5):809-838. PubMed ID: 27928963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Electroacupuncture Therapy Ameliorates Motor Dysfunction via Brain-Derived Neurotrophic Factor and Glial Cell Line-Derived Neurotrophic Factor in a Mouse Model of Parkinson's Disease.
    Pak ME; Ahn SM; Jung DH; Lee HJ; Ha KT; Shin HK; Choi BT
    J Gerontol A Biol Sci Med Sci; 2020 Mar; 75(4):712-721. PubMed ID: 31644786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.